Ignite Creation Date:
2024-05-06 @ 12:49 PM
Last Modification Date:
2024-10-26 @ 1:04 PM
Study NCT ID:
NCT03850314
Status:
UNKNOWN
Last Update Posted:
2019-02-21
First Post:
2019-02-19
Brief Title:
The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters
Sponsor:
Prof Tony hayek MD
Organization:
Rambam Health Care Campus
Study Overview
Official Title:
The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters A Clinical and Ex-vivo Study
Status:
UNKNOWN
Status Verified Date:
2019-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The current study will test the central hypothesis that Glycine supplementation in humans improves Lipid profile and therefore reduces the risk of Atherosclerosis Secondary outcomes including Insulin sensitivity and parameters related to Metabolic Syndrome MetS will also be measured Furthermore a mechanistic study in an ex-vivo model will test the hypothesis that Glycine via its key biosynthetic pathway involving Serine Hydroxymethyltransferase 2 SHMT2 is athero-protective by inhibiting Sterol regulatory element-binding protein 2 SREBP2-mediated cholesterol biosynthesis in murine macrophage-like cell line
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None